RE:RE:Investors in biotechs are a greedy bunchI know it's hard to ignore daily price white noise, but we know what's happening. Year end and some investors want to take their losses to offset gains. Can't blame them. Volumes been light, so if you want to buy back prior to the holidays with the view they may announce something around that time, then you need to see now and the next week or so to buy back 31 days later. So there's some pressure hear around tax loss selling. We had identified that. I would say other than today's last hour puke, the share's been pretty decent around having consistent light buying to match the selling. GUess there was a rush out this afternoon.
But the facts are the facts, just need to be patient. The stock price doesn't change the scientific facts we know
1. They are well advanced in a dosage maximization trial. We know based on the time since start they are at least in a 1.5x normal docetaxol dose level and possibly higher.
2. Even with that much higher dose, there have been no SAEs disclosed yet. We only know of 1 SAE grade 2.
3. Safety has not stopped it yet, that we have heard.
4. We should have a high to maybe very high dosage level it appears
5. We will have a PDC with a very tolerable profit despite the high chemo load.
6. It "implies" that lots of the chemo is going in to the tumor cells and not releaseing freely in the body.
All of that doesn't change and is what the in vitro all showed. So they are on target. A large, safe dose is all one can expect at this point and that's a very good starting point for the extension trial. A few parts of the POC will be affirmed from just that data alone, but maybe not the entire POC. Any signs of efficacy will help proving up those other few bits of the POC we hope to see. So take advantage of this tax-loss selling swoon while it lasts as I can't see it lasting much longer and eventually the news flow will take over the direction of the market sp.
Bucknelly21 wrote: Not sure what your timeline for legacy drugs to be meaningful but it will be years in my opinion
palinc2000 wrote: and far from being risk adversed,,,Paul has or had an excellent reputation prior to joinung THTX
Paul s comment as being EXTREMELY EXCITED about Phase 1 should have been a SP booster .....
Yet Nothing changed after Pauls comments...No upgrades on oncology no new oncology analysts
I cant believe that cancer experts hired by investment firms have not been shown THTX material.
Paul will be judged harshly if Pase 1 turns out to be a nothingburgerI.had high hope after his comment but now hope has diminished and very little expectations,,However I am still high on Nash and revenues of legacy drugs